bezuclastinib
Small molecule
Evidence outlook · regulatory review
Gastrointestinal Stromal Tumor: application under FDA review, decision date 2026-11-30
FDA grants Priority Review for bezuclastinib NDA in GIST (2026-05-28). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Latest reported trial: NCT05208047 · Phase 3 · met primary endpoint · grade pending
Also in development:Systemic Mastocytosis · Phase 2 · under FDA review
Company guidance: regulatory decision expected later this year (Cogent Biosciences, Inc., 10 Aug 2026). “On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30” Source ↗
Company guidance: regulatory filing expected Q4 2026 (Cogent Biosciences, Inc., 30 Jun 2026). “APEX NDA is third submission for bezuclastinib in six months; PEAK and SUMMIT reviews ongoing and on track for anticipated Q4 2026 approval” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05208047 NCT05208047 · Gastrointestinal Stromal Tumor PEAK Part 2 randomized patients with GIST after imatinib to bezuclastinib plus sunitinib or sunitinib alone, open-label, with progression-free survival read by blinded independent central review as the primary endpoint. Cogent reported a median PFS of 16.5 months with the combination and 9.2 months with sunitinib (HR 0.50, 95% CI 0.39 to 0.65), so the primary endpoint was met. Treatment was not blinded, but central blinded review of progression limits that bias. The other registered primaries are pharmacokinetic measures in the non-randomized Parts 1a and 1b. Overall survival was immature at this analysis. Caveat: this result is taken from the company's own report (8-K of 10 November 2025); ClinicalTrials.gov has no posted results. Registry: NCT05208047 | 3 | Part 2: Progression Free Survival (PFS) (approximately 48 months); Parts 1a, 1b and DDI substudy: pharmacokinetics (Cmax, AUC, Tmax) 2025-09-30 | Part 2 randomized comparison, bezuclastinib + sunitinib vs sunitinib alone: median PFS by blinded independent central review 16.5 vs 9.2 months, HR 0.50 (95% CI 0.39 to 0.65); objective response rate 46% vs 26% (data cutoff 30 September 2025; Cogent 8-K of 10 November 2025). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other KIT drugs
barzolvolimab, Velzatinib, Briquilimab, SAR449028. Compare all 5 KIT drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Gastrointestinal Stromal Tumor: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bezuclastinib: this drug | Phase 3 | Small molecule | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 3(overall) | Monoclonal antibody | KIT | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Velzatinib | Phase 3 | Small molecule | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Briquilimab | Phase 1/2(overall) | Monoclonal antibody | KIT | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SAR449028 | —(overall) | Undisclosed | KIT | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent